Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01237990
Recruitment Status : Completed
First Posted : November 10, 2010
Last Update Posted : January 20, 2012
Information provided by (Responsible Party):
Pathfinder Therapeutics

Brief Summary:

This study was designed to confirm that the surgeon is able to perform surface registration of standard liver features used as landmarks during a scheduled laparoscopic liver procedure. Additionally, registrations will be obtained with full insufflation pressure and with half insufflation pressure during the laparoscopic procedure. Under the presence of both insufflation pressures, the surface of the liver will be manually swabbed with the study tracked laparoscopic probe with landmarks noted during data collection. After registration of the liver is obtained, the registration points obtained during this procedure will be evaluated by the surgeon by moving the tracked laparoscopic probe over the liver surface and evaluating the location of the tracked laparoscopic probe displayed on the guidance system 3D image. The surgeon will accept or reject the registration accuracy. Upon completion of the scheduled laparoscopic procedure, the subject will then undergo the open procedure scheduled for the surgical case. An open liver registration will be obtained with manual swabbing of the liver using the study tracked probe and will be accepted or rejected by the surgeon using the process described in the laparoscopic procedure.

In the event that the disease is determined to be too great for surgical repair during the laparoscopic staging procedure, only minimally invasive liver surface data will be acquired and the patient will not be included in the overall study population.

Condition or disease
Liver Cancer

Detailed Description:

The Pathfinder System used during this study is used for data collection purposes only and is not used during the surgical procedure as an image guided system.

Preoperative CT scans, obtained as standard of care, will be used to generate the image guided liver system 3D liver surface images used during the study.

During the laparoscopic procedure, the Pathfinder device will be inserted through the standard laparoscopic ports (5mm or 10mm) being used for the staging procedure.

For the purposes of the study, subjects will be enrolled following the inclusion/exclusion criteria below:


  1. Written informed consent must be obtained.
  2. Patients enrolled must be undergoing a staging laparoscopy for with the intention for conversion to laparotomy.
  3. Patient must be 18 years of age or older.
  4. Women of childbearing age without documented evidence of menopause or sterility must have a negative serum or urine pregnancy test at the time of screening.


  1. Any condition which, in the judgement of the clinical investigator or his designee, might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
  2. Patients that have a condition rendering them unable to understand the nature, scope and possible consequences of this study and therefore unable to give proper consent.
  3. Patients with Cirrhosis of the liver classified as Child-Pugh B or C.
  4. Patients undergoing liver surgery for the purpose of receiving a liver transplant.
  5. Patients with established renal insufficiency (defined as creatinine greater than 2.5 mg/dl), or a condition that requires hemodialysis.

A total study population will include 20 subjects that complete both the laparoscopic and open liver procedures scheduled.

Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures
Study Start Date : August 2010
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Primary Outcome Measures :
  1. The number of accepted liver registrations associated with laparoscopically acquired surface data compared with the number of accepted liver registrations associated with open liver acquired surface data. [ Time Frame: 30 Days ]
    Subjects are followed for the study 30days (+/- 14 days) and are considered to have completed the study following this 30 day follow-up visit.

Secondary Outcome Measures :
  1. Comparison of registration errors from the full and half sufflation pressures to determine an impact of insufflation pressure on registration accuracy. [ Time Frame: 30 Days ]
    Subjects are followed for the study up to 30days (+/- 14 days) and are considered to have completed the study following this 30 day follow-up visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any subject with liver cancer scheduled for a laparoscopic staging and open liver resection procedure.

Inclusion Criteria:

  • Clinical Diagnosis of Liver Cancer
  • Scheduled for liver surgery

Exclusion Criteria:

  • Receiving a liver transplant
  • Kidney failure or dialysis
  • Unable to consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01237990

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Pathfinder Therapeutics
Principal Investigator: William Jarnagin, M.D. Memorial Sloan Kettering Cancer Center

Responsible Party: Pathfinder Therapeutics Identifier: NCT01237990     History of Changes
Other Study ID Numbers: PTI-LC-2009-01
First Posted: November 10, 2010    Key Record Dates
Last Update Posted: January 20, 2012
Last Verified: January 2012

Keywords provided by Pathfinder Therapeutics:

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases